![]() “If we have quality problems at a plant, we have to make a medical decision” about the consequences of banning the use of the drug, Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, testified in October. But a shortage of some critical medicine has prompted the FDA to allow the sale of some Chinese-made drugs that could pose a safety risk, rather than be caught without any supply. There aren’t enough FDA personnel to conduct on-site inspections in China, adding to the worries of many in Congress. Its parent company was also a generous recipient of Chinese subsidies for research, renovations and infrastructure last year. When FDA inspectors visited Henan Lihua Pharmaceutical’s facilities in the city of Anyang two years ago, they found “significant deviations from current good manufacturing practice.” Among the red flags were product release forms stamped in advance to speed up warehousing processes. market share in 10 of its product lines, it said, including drugs used to treat high blood pressure and Alzheimer’s disease. Over the first half of this year, it had received an additional 92 million yuan in state funding.ĭespite the contamination incident, ZHP still leads the U.S. Zhejiang Huahai Pharmaceutical (ZHP), producer of the contaminated valsartan, disclosed in a 2018 annual report that it had received $44.4 million (312 million yuan) in government subsidies. governments have railed against this sort of behavior from China, one of the driving forces behind the 17-month trade war. Some of the companies on the FDA’s warning list also benefit from generous state subsidies. ![]() Gibson noted that a single factory in China made the active pharmaceutical ingredient for a common blood pressure medicine, valsartan, that was found to contain a cancer-causing chemical that has been used to make liquid rocket fuel. ports - regarding Chinese companies has steadily risen, from 19 in 2016 to 23 in 2017 and 28 in 2018. ![]() The number of FDA import alerts - which can lead to a complete blocking of flagged products from entering U.S. “Should we reduce the exports, the medical systems of some western countries will not run well,” he added. “We are at the mercy of others when it comes to computer chips, but we are the world’s largest exporter of raw materials for vitamins and antibiotics,” Li Daokui, a professor of economics at Tsinghua University, said in March 2019 while speaking at the National People’s Conference. In a rare high-profile public comment, one former central bank adviser suggested that China could curb its exports of antibiotics to the United States as a trade war retaliation tool. In a letter to health chiefs last year, Senate Finance Chairman Chuck Grassley cited reports claiming 80 percent of active pharmaceutical ingredients are produced overseas, mostly in China and India. imports of heparin, according to Commerce Department data. imports of penicillin and 40 percent of U.S. imports of acetaminophen, 40 to 45 percent of U.S. imports of hydrocortisone, 70 percent of U.S. Last year, China accounted for 95 percent of U.S. Medicines can be made with lethal contaminants or sold without any real medicine in them, rendering them ineffective.”Ī watchdog report last month by the U.S.-China Economic and Security Review Commission and a recent congressional hearing warn that China hopes of surpassing the United States as the world’s biggest producer of pharmaceutical products. “Medicines can be used as a weapon of war against the United States,” Rosemary Gibson, a senior adviser on health care issues at the bioethics-focused Hastings Center and co-author of “China Rx: Exposing the Risks of America’s Dependence on China for Medicine,” told lawmakers last month. is woefully unprepared to address even minor disruptions in the supply of these drugs.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |